Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. John Lambert to its board of directors (BoD), effective immediately.
Internationally recognized, Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates (ADCs). He previously served in multiple senior scientific and executive leadership roles at ImmunoGen—now AbbVie (NYSE: ABBV), including chief scientific officer, executive vice president of research, and member of the executive committee.
In a statement, Sébastien Plouffe, CEO of Defence, commented, “We are extremely proud to welcome Dr. Lambert to Defence’s BoD. John is one of the most respected pioneers in the ADC field and has contributed to the development of technologies and therapeutics that have had a major impact on cancer treatment worldwide. His scientific vision, leadership experience, and deep understanding of ADC development will be instrumental as Defence advances its ACCUM platform and expands its ACCUM-enabled ADC programs and partnerships. Having someone of John’s caliber joining our board is a tremendous validation of the potential of our technology.”
